Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 9/2004

01-05-2004 | Aids Drug Profile

Micafungin

A Viewpoint by Raj Chopra

Author: Raj Chopra

Published in: Drugs | Issue 9/2004

Login to get access

Excerpt

Micafungin is a novel antifungal agent that exhibits activity against β-(1,3)-D-glycan synthase found in the fungal wall. This specific antifungal activity should theoretically at least, result in limited adverse effects and this is confirmed by the favourable tolerability profile. In vitro, the drug shows activity against Candida spp. and Aspergillus spp., but does not have activity against dimorphic fungi such as Cryptococcus spp. In particular, in vitro, there is no evidence of antagonism when micafungin is combined with other antifungal agents including amphotericin B. …
Metadata
Title
Micafungin
A Viewpoint by Raj Chopra
Author
Raj Chopra
Publication date
01-05-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 9/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464090-00005

Other articles of this Issue 9/2004

Drugs 9/2004 Go to the issue

Adis Drug Profile

Lanthanum Carbonate

Review Article

Antifungals in Systemic Neonatal Candidiasis

Guest Commentary

Micafungin

Adis Drug Profile

Lanthanum Carbonate

Adis Drug Profile

Lanthanum Carbonate

Adis Drug Profile

Micafungin